Metal Nanoparticles for the Treatment and Diagnosis of Neurodegenerative Brain Diseases

Author(s): Valentina Vio, Maria Jose Marchant, Eyleen Araya*, Marcelo J. Kogan*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 13 , 2017

Become EABM
Become Reviewer
Call for Editor


This review focuses on the application of metal nanoparticles in the diagnosis and treatment of Alzheimer’s and Parkinson’s diseases. Metal nanoparticles present interesting physicochemical properties that can be applied to increase biomarker detection sensitivities in vitro and in vivo. Furthermore, these nanoparticles could be used in different strategies for the treatment of central nervous system diseases, particularly in regards to drug delivery. Herein, specific potential applications of metal nanoparticles are separately discussed for the contexts of in vitro diagnoses and treatments. Briefly, research using surface plasmon resonance methodologies has mainly used these nanoparticles for the in vitro detection of Aβ and, to a lesser extent, of α-synuclein. Regarding treatment approaches, in vitro studies have focused on using metal nanoparticles to manipulate the Aβ aggregation, thus reducing toxicity. Furthermore, in vivo applications of metal nanoparticles are also discussed, with many of the existing studies focusing on a magnetic nanoparticle-detection of Aβ through magnetic resonance imaging and, to a lesser degree, extension fluorescence techniques. Finally, conclusions and perspectives are provided regarding the real potential for using metal nanoparticles in the treatment and diagnosis of central nervous system diseases.

Keywords: Theranostic, imaging, neurodegenerative disorders, drug delivery, physicochemical properties, nanoparticle-detection.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1916 - 1926]
Pages: 11
DOI: 10.2174/1381612823666170105152948
Price: $65

Article Metrics

PDF: 34
PRC: 1